Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.62 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5078454 | 1.00 | DPP4 (0.62) | DPP4DPP8DPP7HDAC8PARP1 | |
| SCHEMBL5137673 | 0.90 | DPP8 (0.64) | DPP4DPP8DPP7HDAC8PARP1 | |
| SCHEMBL5137675 | 0.90 | DPP8 (0.64) | DPP4DPP8DPP7HDAC8PARP1 | |
| SCHEMBL8232343 | 0.88 | DPP4 (0.62) | DPP4DPP8DPP7HDAC8DPP9 | |
| Hydrochloric Acid SCHEMBL23834108 | 0.87 | DPP8 (0.53) | DPP4DPP8DPP7HDAC8PARP1 | |
| Hydrochloric Acid SCHEMBL23834111 | 0.87 | DPP8 (0.53) | DPP4DPP8DPP7HDAC8PARP1 | |
| Hydrochloric Acid SCHEMBL23833867 | 0.84 | PARP1 (0.55) | DPP4DPP8DPP7HDAC8PARP1 | |
| Hydrochloric Acid SCHEMBL23833870 | 0.84 | PARP1 (0.55) | DPP4DPP8DPP7HDAC8PARP1 | |
| SCHEMBL14523899 | 0.82 | DPP4 (0.71) | DPP4DPP8DPP7HDAC8DPP9 | |
| Hydrochloric Acid SCHEMBL23834262 | 0.81 | PARP1 (0.47) | DPP4DPP8DPP7HDAC8PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101400699-A | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions | BRISTOL MYERS SQUIBB CO (US) | 2009-04-01 | — | — | CN | claimed |
| EP-1976873-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Brystol-Myers Squibb Company (US) | 2008-10-08 | — | — | EP | claimed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | claimed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | DPP4 14/4885DPP8 41/4885DPP7 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.